Edition:
United Kingdom

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

4.81USD
20 Apr 2018
Change (% chg)

$-0.02 (-0.41%)
Prev Close
$4.83
Open
$4.85
Day's High
$4.86
Day's Low
$4.80
Volume
2,445
Avg. Vol
20,893
52-wk High
$7.73
52-wk Low
$4.42

Select another date:

Fri, Apr 20 2018

BRIEF-Therapix Biosciences - Co Terminated Research & License Agreement Between Co, Yissum Research Development Co

* THERAPIX BIOSCIENCES - ON MARCH 18, 2018 CO TERMINATED RESEARCH & LICENSE AGREEMENT BETWEEN CO, YISSUM RESEARCH DEVELOPMENT CO, DATED MARCH 30, 2017 Source text: (https://bit.ly/2F372wh) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Therapix Biosciences Announces Topline Results Of Phase IIA Study At Yale University For Tourette Syndrome Program

* THERAPIX BIOSCIENCES ANNOUNCES TOPLINE RESULTS OF PHASE IIA STUDY AT YALE UNIVERSITY FOR TOURETTE SYNDROME PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Therapix Biosciences Says U.S. FDA Cleared IND For THX-110 In Treatment Of Chronic Low Back Pain

* THERAPIX BIOSCIENCES - U.S. FDA CLEARED IND FOR THX-110 IN TREATMENT OF CHRONIC LOW BACK PAIN

BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2

* THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018

BRIEF-Therapix Biosciences Announces Expansion Into Precision Medicine Through New Fully-Owned Subsidiary

* THERAPIX BIOSCIENCES ANNOUNCES EXPANSION INTO PRECISION MEDICINE THROUGH NEW FULLY-OWNED SUBSIDIARY AND PROVIDES CORPORATE UPDATE TODAY AT THE BIOTECH SHOWCASE™ 2018

BRIEF-Therapix Biosciences and Co's CFO Entered Into A "Mutually-Amicable" Separation Agreement

* THERAPIX BIOSCIENCES SAYS CO AND CFO JOSH BLACHER ENTERED INTO A "MUTUALLY-AMICABLE" SEPARATION AGREEMENT ON DECEMBER 19 - SEC FILING

Therapix expects to have results of Tourette's drug trial by end of first quarter

TEL AVIV Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

Therapix expects to have results of Tourette's drug trial by end of Q1

TEL AVIV, Dec 4 Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

BRIEF-Therapix Biosciences plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids

* Therapix Biosciences Ltd plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids Source text for Eikon: Further company coverage:

BRIEF-Therapix Biosciences Q3 loss per share $0.30

* Therapix Biosciences reports third quarter 2017 financial results and provides business update

Select another date: